OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
CN Stock MarketDetailed Quotes
603186 Zhejiang Wazam New Materials
- 25.63
- -1.21-4.51%
Not Open Apr 1 15:00 CST
3.64BMarket Cap-37.36P/E (TTM)
26.52High25.63Low126.16KlotVolume26.38Open26.84Pre Close329.37MTurnover8.88%Turnover RatioLossP/E (Static)142.01MShares34.9052wk High2.59P/B3.64BFloat Cap18.9552wk Low29.52Limit Up142.01MShs Float68.87Historical High24.16Limit Down3.32%Amplitude6.25Historical Low--Dividend TTM26.11Avg Price68.35KlotAsk--Div YieldTTM100Lot Size51.16KlotBid
Zhejiang Wazam New Materials Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 14.97%3.86B | 13.08%2.82B | 22.83%1.94B | 12.79%854.79M | 2.31%3.36B | 5.02%2.5B | -1.07%1.58B | -9.45%757.89M | -9.23%3.29B | -11.23%2.38B |
| Operating revenue | 14.97%3.86B | 13.08%2.82B | 22.83%1.94B | 12.79%854.79M | 2.31%3.36B | 5.02%2.5B | -1.07%1.58B | -9.45%757.89M | -9.23%3.29B | -11.23%2.38B |
| Other operating revenue | 30.00%86.39M | ---- | 29.83%44.24M | ---- | 33.34%66.45M | ---- | 35.99%34.08M | ---- | -56.78%49.84M | ---- |
| Total operating cost | 12.20%3.97B | 12.57%2.89B | 21.05%1.96B | 11.89%876.06M | 7.38%3.54B | 9.93%2.56B | 5.50%1.62B | -3.90%782.95M | -3.59%3.3B | -5.94%2.33B |
| Operating cost | 13.37%3.47B | 13.36%2.53B | 22.67%1.73B | 14.49%768.5M | 7.12%3.06B | 8.98%2.23B | 4.45%1.41B | -5.35%671.24M | -5.40%2.86B | -6.93%2.05B |
| Operating tax surcharges | 18.68%19.36M | 13.65%13.2M | 3.40%8.22M | -19.51%2.82M | 17.40%16.31M | 43.28%11.62M | 105.23%7.95M | -9.88%3.5M | 34.45%13.9M | 40.22%8.11M |
| Operating expense | 7.89%94.62M | 7.68%65.22M | 7.24%42.43M | 12.28%20.69M | 10.32%87.7M | 9.52%60.58M | 14.76%39.56M | 12.24%18.43M | 2.17%79.49M | 0.39%55.31M |
| Administration expense | -5.78%112.41M | -1.72%81.95M | -2.24%52.38M | -0.98%26.76M | 5.45%119.31M | 6.10%83.39M | 8.39%53.58M | 3.85%27.02M | 10.92%113.15M | 5.97%78.6M |
| Financial expense | 26.29%70.57M | 110.85%59.11M | 181.62%35.59M | 22.19%17.27M | 99.24%55.88M | 153.58%28.04M | -11.74%12.64M | -17.06%14.13M | -52.79%28.05M | -72.24%11.06M |
| -Interest expense (Financial expense) | 29.60%70.9M | 71.80%54.13M | 88.04%35.64M | 78.30%16.59M | 24.93%54.71M | -10.23%31.51M | -22.48%18.95M | -26.56%9.31M | 3.30%43.79M | 20.62%35.1M |
| -Interest Income (Financial expense) | 28.09%-6.8M | 24.49%-5.52M | 23.93%-4.08M | 6.14%-1.94M | 3.64%-9.45M | -5.10%-7.31M | -87.41%-5.37M | -123.23%-2.07M | -403.22%-9.81M | -333.08%-6.95M |
| Research and development | 2.19%200.89M | -7.69%139.36M | -4.20%90.54M | -17.69%40.02M | -2.50%196.59M | 12.93%150.97M | 15.54%94.5M | 15.20%48.62M | 37.74%201.63M | 25.30%133.69M |
| Credit Impairment Loss | -28.06%-10.63M | 72.21%-1.11M | 15.70%-2.59M | 40.04%-489.13K | -80.27%-8.3M | -70.36%-4M | -40.20%-3.07M | -44.86%-815.74K | -115.16%-4.61M | -107.71%-2.35M |
| Asset Impairment Loss | -437.93%-59.94M | 24.19%-6.73M | -22.21%-4.57M | -69.28%-2.83M | -33.55%-11.14M | 7.90%-8.88M | 43.23%-3.74M | -172.68%-1.67M | -253.15%-8.34M | -129.13%-9.64M |
| Other net revenue | -94.70%1.01M | 343.66%39.56M | 134.91%22.57M | 108.74%14.28M | 7.28%18.99M | 22.81%8.92M | 2.21%9.61M | -25.17%6.84M | -70.99%17.7M | -83.55%7.26M |
| Fair value change income | -241.44%-843.35K | 103.52%156.68K | 86.25%-962.59K | 29.70%-2.13M | -70.05%596.25K | 16.58%-4.45M | -538.58%-7M | -1,781.10%-3.02M | 678.56%1.99M | -208.24%-5.33M |
| Invest income | 46.52%-4.59M | 46.45%-2.56M | -8,325.04%-2.94M | -126.88%-989.77K | 1.44%-8.58M | -2.87%-4.78M | 98.00%-34.86K | 150.07%3.68M | -237.19%-8.71M | -184.08%-4.65M |
| Asset deal income | 113.72%73.97K | 146.48%75.12K | 79.72%75.12K | --79.23 | -4,091.91%-539.33K | ---161.64K | --41.8K | ---- | 8,393.82%13.51K | ---- |
| Other revenue | 63.85%76.94M | 59.44%49.73M | 43.32%33.56M | 138.92%20.72M | 25.72%46.96M | 6.69%31.19M | 11.43%23.42M | -3.74%8.67M | 38.43%37.35M | 107.60%29.23M |
| Operating profit | 33.97%-104.29M | 60.99%-22.43M | 105.57%1.72M | 61.63%-6.99M | -2,071.28%-157.95M | -208.48%-57.51M | -143.83%-30.89M | -158.04%-18.22M | -96.95%8.01M | -78.23%53.01M |
| Add:Non operating Income | -39.89%1.19M | -51.39%832.32K | -49.23%866.24K | 1,674.21%513.75K | -21.99%1.98M | -20.66%1.71M | 357.73%1.71M | -70.70%28.96K | 235.10%2.54M | 500.99%2.16M |
| Less:Non operating expense | -9.99%999.89K | 7.21%737.11K | 539.05%688.34K | -68.34%26.64K | 55.53%1.11M | -1.87%687.56K | -69.62%107.71K | -72.16%84.15K | -64.34%714.25K | -58.40%700.65K |
| Total profit | 33.73%-104.09M | 60.45%-22.34M | 106.48%1.9M | 64.42%-6.5M | -1,696.01%-157.07M | -203.70%-56.48M | -141.55%-29.29M | -158.60%-18.28M | -96.23%9.84M | -77.51%54.47M |
| Less:Income tax cost | 81.51%-6.78M | 38.36%-16.93M | 53.25%-8.66M | 45.23%-5.69M | -19.11%-36.68M | -177.75%-27.47M | -1,150.48%-18.52M | -1,852.78%-10.38M | -245.55%-30.8M | -141.10%-9.89M |
| Net profit | 19.17%-97.31M | 81.38%-5.4M | 198.02%10.56M | 89.65%-817.36K | -396.24%-120.39M | -145.08%-29.01M | -114.96%-10.77M | -124.89%-7.89M | -83.08%40.64M | -70.50%64.36M |
| Net profit from continuing operation | 19.17%-97.31M | 81.37%-5.4M | 198.02%10.56M | 89.65%-817.36K | -396.25%-120.39M | -145.08%-29.01M | -114.96%-10.77M | -124.89%-7.89M | -83.08%40.64M | -70.50%64.36M |
| Net income from discontinuing operating | -84.25%652.05 | --652.05 | ---- | ---- | --4.14K | ---- | ---- | ---- | ---- | ---- |
| Less:Minority Profit | -7.11%121.03K | -17.41%1.24M | 16.94%584.61K | 282.46%175.38K | -97.14%130.29K | -60.37%1.5M | -81.51%499.91K | -110.72%-96.12K | 128.30%4.56M | 172.94%3.79M |
| Net profit of parent company owners | 19.16%-97.43M | 78.23%-6.65M | 188.49%9.97M | 87.27%-992.74K | -434.03%-120.52M | -150.39%-30.52M | -116.27%-11.27M | -125.30%-7.8M | -84.85%36.08M | -72.06%60.57M |
| Earning per share | ||||||||||
| Basic earning per share | 18.82%-0.69 | 77.27%-0.05 | 187.50%0.07 | 80.00%-0.01 | -440.00%-0.85 | -151.16%-0.22 | -116.33%-0.08 | -122.73%-0.05 | -85.12%0.25 | -71.90%0.43 |
| Diluted earning per share | 18.82%-0.69 | 77.27%-0.05 | 187.50%0.07 | 80.00%-0.01 | -440.00%-0.85 | -153.66%-0.22 | -117.39%-0.08 | -125.00%-0.05 | -85.12%0.25 | -73.20%0.41 |
| Other composite income | 318.68K | |||||||||
| Other composite income of parent company owners | ---- | ---- | ---- | ---- | --254.94K | ---- | ---- | ---- | ---- | ---- |
| Other composite income of minority owners | ---- | ---- | ---- | ---- | --63.74K | ---- | ---- | ---- | ---- | ---- |
| Total composite income | 18.96%-97.31M | 81.38%-5.4M | 198.02%10.56M | 89.65%-817.36K | -395.46%-120.07M | -145.08%-29.01M | -114.96%-10.77M | -124.89%-7.89M | -83.08%40.64M | -70.50%64.36M |
| Total composite income of parent company owners | 18.99%-97.43M | 78.23%-6.65M | 188.49%9.97M | 87.27%-992.74K | -433.33%-120.26M | -150.39%-30.52M | -116.27%-11.27M | -125.30%-7.8M | -84.85%36.08M | -72.06%60.57M |
| Total composite income of minority owners | -37.62%121.03K | -17.41%1.24M | 16.94%584.61K | 282.46%175.38K | -95.74%194.02K | -60.37%1.5M | -81.51%499.91K | -110.72%-96.12K | 128.30%4.56M | 172.94%3.79M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Zhonghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhonghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Zhonghui Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.